Giant Biogene Holding Past Earnings Performance
Past criteria checks 6/6
Giant Biogene Holding has been growing earnings at an average annual rate of 17.1%, while the Personal Products industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 31.8% per year. Giant Biogene Holding's return on equity is 33.1%, and it has net margins of 41.2%.
Key information
17.1%
Earnings growth rate
19.5%
EPS growth rate
| Personal Products Industry Growth | 8.8% |
| Revenue growth rate | 31.8% |
| Return on equity | 33.1% |
| Net Margin | 41.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Giant Biogene Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,524 | 1,452 | 1,260 | 75 |
| 30 Sep 23 | 3,255 | 1,252 | 1,183 | 67 |
| 30 Jun 23 | 2,985 | 1,052 | 1,106 | 59 |
| 31 Mar 23 | 2,675 | 874 | 962 | 52 |
| 31 Dec 22 | 2,364 | 696 | 818 | 44 |
| 31 Dec 21 | 1,552 | 809 | 419 | 25 |
| 31 Dec 20 | 1,190 | 826 | 187 | 13 |
| 31 Dec 19 | 957 | 552 | 122 | 11 |
Quality Earnings: 2367 has high quality earnings.
Growing Profit Margin: 2367's current net profit margins (41.2%) are higher than last year (29.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2367's earnings have grown by 17.1% per year over the past 5 years.
Accelerating Growth: 2367's earnings growth over the past year (108.6%) exceeds its 5-year average (17.1% per year).
Earnings vs Industry: 2367 earnings growth over the past year (108.6%) exceeded the Personal Products industry -1.7%.
Return on Equity
High ROE: 2367's Return on Equity (33.1%) is considered high.